Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, October 1998, p. 2650-2655, Vol. 42, No. 10
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Pharmacodynamics of Gatifloxacin in Cerebrospinal
Fluid in Experimental Cephalosporin-Resistant Pneumococcal
Meningitis
Irja
Lutsar,*
Ian R.
Friedland,
Loretta
Wubbel,
Cynthia C.
McCoig,
Hasan S.
Jafri,
Winston
Ng,
Faryal
Ghaffar, and
George H.
McCracken Jr.
The University of Texas Southwestern Medical
Center, Dallas, Texas
Received 9 February 1998/Returned for modification 31 May
1998/Accepted 20 July 1998
The purpose of this study was to evaluate the cerebrospinal fluid
(CSF) pharmacodynamics of a new fluoroquinolone, gatifloxacin (AM-1155), in experimental pneumococcal meningitis. The penetration of
gatifloxacin into CSF, calculated as the percentage of the area under
the concentration-time curve (AUC) in CSF over the AUC in blood, was 46 to 56%. Gatifloxacin showed linear pharmacokinetics in CSF, and 1 h after intravenous dosages of 7.5, 15, or 30 mg/kg of body weight,
peak CSF concentrations were 0.46 ± 0.08 (mean ± standard
deviation), 0.94 ± 0.16, and 1.84 ± 0.5 µg/ml,
respectively. The elimination half-life of gatifloxacin in CSF was 3.8 to 5.6 h (compared with 2.7 to 3.2 h in blood). There was a
significant interrelationship among the highest measured values of
gatifloxacin in blood and CSF/minimal bactericidal concentration
(Cpeak/MBC), the time antibiotic concentrations
exceeded the MBC (T > MBC), and AUC/MBC
(r = 0.94); in single-dose experiments, each
correlated significantly with the bacterial killing rate. Divided-dose
regimens, resulting in greater T > MBC values but
lower Cpeak/MBC ratios, were more effective in
terms of bacterial clearance compared with corresponding single-dose
regimens. Gatifloxacin therapy was as effective as currently
recommended regimens (e.g., a combination of ceftriaxone and
vancomycin) against this highly cephalosporin-resistant pneumococcal
strain. The bactericidal activity of gatifloxacin in CSF was closely
related to the AUC/MBC ratio, but maximal activity was achieved only
when drug concentrations exceeded the MBC for the entire dosing
interval.
*
Corresponding author. Mailing address: Department of
Pediatrics, Southwestern Medical Center, 5323 Harry Hines Blvd.,
Dallas, TX 75235-9063. Phone: (214) 648-3082. Fax: (214) 648-2961. E-mail: GMCCRA{at}mednet.swmed.edu.
Antimicrobial Agents and Chemotherapy, October 1998, p. 2650-2655, Vol. 42, No. 10
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Capparelli, E. V., Reed, M. D., Bradley, J. S., Kearns, G. L., Jacobs, R. F., Damle, B. D., Blumer, J. L., Grasela, D. M.
(2005). Pharmacokinetics of Gatifloxacin in Infants and Children. Antimicrob. Agents Chemother.
49: 1106-1112
[Abstract]
[Full Text]
-
Rodriguez, J. C., Cebrian, L., Lopez, M., Ruiz, M., Jimenez, I., Royo, G.
(2004). Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother
53: 441-444
[Abstract]
[Full Text]
-
Rodriguez-Cerrato, V., McCoig, C. C., Saavedra, J., Barton, T., Michelow, I. C., Hardy, R. D., Bowlware, K., Iglehart, J., Katz, K., McCracken, G. H. Jr
(2003). Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci. Antimicrob. Agents Chemother.
47: 211-215
[Abstract]
[Full Text]
-
Takahata, M., Yamada, H., Morita, T., Furubou, S., Minami, S., Todo, Y., Watanabe, Y., Narita, H.
(2002). Evaluation of T-3811ME (BMS-284756), a New Des-F(6)-Quinolone, for Treatment of Meningitis Caused by Penicillin-Resistant Streptococcus pneumoniae in Rabbits. Antimicrob. Agents Chemother.
46: 1760-1765
[Abstract]
[Full Text]
-
Rodriguez-Cerrato, V., Ghaffar, F., Saavedra, J., Michelow, I. C., Hardy, R. D., Iglehart, J., Olsen, K., McCracken, G. H. Jr.
(2001). BMS-284756 in Experimental Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother.
45: 3098-3103
[Abstract]
[Full Text]
-
Destache, C. J., Pakiz, C. B., Larsen, C., Owens, H., Dash, A. K.
(2001). Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. J Antimicrob Chemother
47: 611-615
[Abstract]
[Full Text]
-
Perrig, M., Acosta, F., Cottagnoud, M., Gerber, C. M., Tauber, M. G., Cottagnoud, P.
(2001). Efficacy of gatifloxacin alone and in combination with cefepime against penicillin-resistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro. J Antimicrob Chemother
47: 701-704
[Abstract]
[Full Text]
-
Smirnov, A., Wellmer, A., Gerber, J., Maier, K., Henne, S., Nau, R.
(2000). Gemifloxacin Is Effective in Experimental Pneumococcal Meningitis. Antimicrob. Agents Chemother.
44: 767-770
[Abstract]
[Full Text]
-
Fitoussi, F., Doit, C., Geslin, P., Bingen, E.
(1999). Killing Activities of Trovafloxacin Alone and in Combination with beta -Lactam Agents, Rifampin, or Vancomycin against Streptococcus pneumoniae Isolates with Various Susceptibilities to Extended-Spectrum Cephalosporins at Concentrations Clinically Achievable in Cerebrospinal Fluid. Antimicrob. Agents Chemother.
43: 2372-2375
[Abstract]
[Full Text]
-
Michelet, C., Leib, S. L., Bentue-Ferrer, D., Täuber, M. G.
(1999). Comparative Efficacies of Antibiotics in a Rat Model of Meningoencephalitis Due to Listeria monocytogenes. Antimicrob. Agents Chemother.
43: 1651-1656
[Abstract]
[Full Text]
-
Lutsar, I., Friedland, I. R., Jafri, H. S., Wubbel, L., Ng, W., Ghaffar, F., McCracken, G. H. Jr.
(1999). Efficacy of Gatifloxacin in Experimental Escherichia coli Meningitis. Antimicrob. Agents Chemother.
43: 1805-1807
[Abstract]
[Full Text]